Comparable Effects of Lanreotide Autogel and Octreotide LAR on GH, IGF-I Levels and Patient Satisfaction
Status:
Completed
Trial end date:
2004-12-01
Target enrollment:
Participant gender:
Summary
The morbidity and the mortality in acromegalic patients closely correspond to growth hormone
(GH) levels and therefore efficient long-term treatment is important.
Neurosurgery is the first choice of treatment in acromegalic patients. Surgery normalizes GH
levels in about 80% of patients with microadenomas, but less than 50 % of patients with
macroadenomas respond sufficiently to surgery alone. In most patients, additional medical
therapy is therefore needed.
Somatostatin analogues have successfully been used in treatment of acromegaly if surgery or
radiotherapy can not lead to normal GH and IGF-I levels. Lanreotide Autogel (LAN) is a new
formulation of lanreotide consisting of a prolonged release aqueous formulation, which can be
injected intramuscularly or deep subcutaneously once every 28 days.
Aim
The aim of the present study was to compare the efficacy of OCT and LAN in obtaining GH and
IGF-I levels according to the 2000 Consensus. Furthermore, we wanted to evaluate which
treatment modality resulted in the lowest possible IGF-I and GH levels and the highest
patient satisfaction.